66909-27-1

Usage

Uses

Used in Pharmaceutical Industry:
5-Methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid is used as an intermediate in the synthesis of various pharmaceuticals for its potential to contribute to the development of new drugs. Its unique structure and properties make it a valuable component in the creation of innovative medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid is utilized as an intermediate in the synthesis of agrochemicals, particularly those with antimicrobial and antifungal properties. Its ability to inhibit the growth of certain strains makes it a candidate for use in products aimed at controlling microbial infections in agricultural settings.
Used in Antimicrobial Applications:
5-Methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid is employed as an antimicrobial agent for its capacity to inhibit the growth of certain bacterial strains. This property makes it a potential candidate for use in treatments and products designed to combat microbial infections.
Used in Antifungal Applications:
Similarly, 5-Methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid is used as an antifungal agent, leveraging its ability to suppress the growth of specific fungal strains. This application is particularly relevant in the development of antifungal medications and treatments for various fungal infections.
Used in Drug Development:
5-Methyl-6-oxo-1,6-dihydro-pyridine-3-carboxylic acid is used as a building block in drug development due to its potential to be incorporated into new pharmaceutical compounds. Its unique characteristics position it as a valuable component in the design and synthesis of innovative drugs with diverse therapeutic applications.

Upstream product

• 124-38-9 carbon dioxide 
• 89488-30-2 5-bromo-3-methylpyridin-2(1H)-one 
• 66909-31-7 methyl 6-hydroxy-5-methylnicotinate 

Relevant academic research and scientific papers

Discovery of a Potent and Selective ATAD2 Bromodomain Inhibitor with Antiproliferative Activity in Breast Cancer Models

ATAD2 is an epigenetic bromodomain-containing target which is overexpressed in many cancers and has been suggested as a potential oncology target. While several small molecule inhibitors have been described in the literature, their cellular activity has proved to be underwhelming. In this work, we describe the identification of a novel series of ATAD2 inhibitors by high throughput screening, confirmation of the bromodomain region as the site of action, and the optimization campaign undertaken to improve the potency, selectivity, and permeability of the initial hit. The result is compound 5 (AZ13824374), a highly potent and selective ATAD2 inhibitor which shows cellular target engagement and antiproliferative activity in a range of breast cancer models.

PYRIDINONES

The present invention encompasses compounds of general formula (I) wherein the groups R1 to R3 and X1 through X6 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

PYRIDINONES

The present invention encompasses compounds of general formula (I) wherein the groups R1 to R3 and X1 through X6 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.

Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor

A series of 2-pyridone-containing imidazoline derivatives was synthesized and evaluated as neuropeptide Y Y5 receptor antagonists. Optimization of the 2-pyridone structure on the 2-position of the imidazoline ring led to identification of 1-(difluoromethy